Has Peter Wade received payments from drug or device companies?

Yes. Drug and device makers reported $302,157 in general payments to Peter Wade across 331 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Wade did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Wade come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Wade

Neurology · Hartford, CTNPI 1275636326

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $222,913 of the $302,157 with a category attached, or 73.8%. 15 manufacturers reported payments, led by Biogen at 36.6% of the total. Reporting peaked in 2019 at $204,652 and has fallen 100.0% since, to $71 in 2022. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$302,157in general payments, 2019–2025

Across 331 payments — averaging $912.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$111K
Genentech USA, Inc.$58K
Bristol Myers Squibb$44K
EMD Serono, Inc.$34K
Sanofi$27K
Mallinckrodt Enterprises LLC$8K
plus $20K from 9 others

What the payments were for

Consulting fees$47,43916%
Speaking & faculty fees$222,91374%
Travel & lodging$24,2768%
Food & beverage$7,4502%
Education$800%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	104	$110,563
Genentech USA, Inc.	46	$57,875
Bristol Myers Squibb	44	$44,127
EMD Serono, Inc.	48	$34,413
Sanofi	32	$27,001
Mallinckrodt Enterprises LLC	4	$7,755
Novartis	29	$7,627
TG Therapeutics, Inc.	7	$4,942
Mallinckrodt Hospital Products Inc.	3	$4,211
E.r. Squibb & Sons, L.L.C.	4	$3,312
Genentech, Inc.	5	$247
Acorda Therapeutics, Inc	2	$31
Merz North America, Inc.	1	$23
AbbVie	1	$17
Teva Pharmaceuticals USA, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OCREVUS$57,093
TYSABRI$49,246
Mavenclad$32,538
Ozanimod$31,769
AUBAGIO$20,329
TECFIDERA$15,676
ZEPOSIA$15,173
ACTHAR$11,920
Vumerity$9,245
LEMTRADA$5,864
MAYZENT$3,260
GILENYA$2,660
AIMOVIG$801
KESIMPTA$125
Rebif$125

How this compares

$302,157 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut →

Other neurology in Hartford

Brian WongHartford$16K
Lawrence BluthHartford$15K
Peter McAllisterFairfield$2.3M
Stewart TepperStamford$1.2M
Sharon StollNew Haven$822K
Mary BaileyNew Haven$630K
Wanda Castro-BorreroFarmington$553K
Derek SmithNorwich$469K
Deena KuruvillaWestport$440K
Duarte MachadoCheshire$426K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →